XORTX Therapeutics Inc. (XRTX)
$0.5301
Rating:
Recommendation:
-
| Symbol | XRTX |
|---|---|
| Price | $0.5301 |
| Beta | 0.188 |
| Volume Avg. | 0.04M |
| Market Cap | 9.536M |
| Shares () | - |
| 52 Week Range | 0.41-1.24 |
| 1y Target Est | - |
| DCF Unlevered | XRTX DCF -> | |
|---|---|---|
| DCF Levered | XRTX LDCF -> | |
| ROE | - | |
| ROA | - | |
| Operating Margin | - | |
| Debt / Equity | - | |
| P/E | -1.29 | Sell |
| P/B | - |
Latest XRTX news
About
Download (Excel)XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.